Avrupa Birliği -
İsveççe -
EMA (European Medicines Agency)
tecvayli
janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiska medel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
Avrupa Birliği -
İsveççe -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversering av neuromuskulär blockad som induceras av rocuronium eller vekuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Avrupa Birliği -
İsveççe -
EMA (European Medicines Agency)
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostata tumörer, kastrering-resistent - antineoplastiska medel - treatment of adult patients with prostate cancer.
Avrupa Birliği -
İsveççe -
EMA (European Medicines Agency)
bekemv
amgen technology (ireland) uc - eculizumab - hemoglobinuri, paroxysmal - immunsuppressiva - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). bevis på klinisk nytta som är visat att patienter med hemolys med kliniska symptom(s) tyder på en hög sjukdomsaktivitet, oavsett transfusion historia (se avsnitt 5.
Avrupa Birliği -
İsveççe -
EMA (European Medicines Agency)
talvey
janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiska medel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.